Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Sanara MedTech Inc.
Sanara MedTech Inc. News
Mar 3, 2026 - globenewswire.com
Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
Feb 17, 2026 - globenewswire.com
Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
Jan 23, 2026 - globenewswire.com
Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance
Jan 7, 2026 - globenewswire.com
Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE® Advanced Surgical Solution
Sanara MedTech Inc. Quantitative Score

About Sanara MedTech Inc.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Sanara MedTech Inc. Financials
Table Compare
Compare SMTI metrics with: | |||
|---|---|---|---|
Earnings & Growth | SMTI | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SMTI | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SMTI | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SMTI | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Sanara MedTech Inc. Income
Sanara MedTech Inc. Balance Sheet
Sanara MedTech Inc. Cash Flow
Sanara MedTech Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Sanara MedTech Inc. Executives
| Name | Role |
|---|---|
| Jacob A. Waldrop | Chief Operating Officer |
| Bill Fitzgerald | Chief Compliance Officer |
| Seth Yon | President, Chief Executive Officer & Director |
| Tyler Palmer | Chief Corporate Development & Strategy Officer |
| Ashley Mackey | Principal Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Jacob A. Waldrop | Chief Operating Officer | Male | 466.67K | |
| Bill Fitzgerald | Chief Compliance Officer | Male | -- | |
| Seth Yon | President, Chief Executive Officer & Director | Male | -- | |
| Tyler Palmer | Chief Corporate Development & Strategy Officer | Male | -- | |
| Ashley Mackey | Principal Accounting Officer | Female | 1986 | -- |
Sanara MedTech Inc. Insider Trades
| Date | 1 Mar |
| Name | Yon Seth D |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 491 |
| Date | 25 Feb |
| Name | Yon Seth D |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 873 |
| Date | 25 Feb |
| Name | Waldrop Jacob A. |
| Role | Chief Operating Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 714 |
| Date | 25 Feb |
| Name | Taylor Elizabeth B |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 437 |
| Date | 25 Feb |
| Name | Mackey Ashley M |
| Role | Controller |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 149 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 Mar | Yon Seth D | Chief Executive Officer | Disposed | F-InKind | 491 |
| 25 Feb | Yon Seth D | Chief Executive Officer | Disposed | F-InKind | 873 |
| 25 Feb | Waldrop Jacob A. | Chief Operating Officer | Disposed | F-InKind | 714 |
| 25 Feb | Taylor Elizabeth B | Chief Financial Officer | Disposed | F-InKind | 437 |
| 25 Feb | Mackey Ashley M | Controller | Disposed | F-InKind | 149 |